The Impact of cfDNA Screening on the Frequency of Invasive Procedures in a Geographically Diverse Private Network
09 March 2017
25 May 2017
30 June 2017 (eFirst)
Objective Cell-free fetal DNA (cfDNA) screening has had a dramatic impact in obstetrics. We examined the impact of cfDNA screening in a network of geographically diverse referral maternal–fetal medicine (MFM) private practices.
Study Design Data were derived from the genetic clinics of 16 testing centers from a wide geographic area and included all women undergoing either amniocentesis or chorionic villus sampling (CVS) during a 6-month control period versus a 30-month study period.
Results During the control period, there were 193 amniocenteses and 47 CVS/month. During the last 6 months of the study, amniocenteses dropped to 52/month and CVS to 18/month. Positive aneuploid test results per procedure increased from 6.9% during the control period to 15.0% during the last 6 months of the study period. However, the overall number of aneuploidy results decreased from 16.7/month to of 10.5/month.
Conclusion Our study demonstrates the dramatic changes in the era of cfDNA screening on reducing the frequency of amniocentesis and CVS associated with a higher percentage of positive results per procedure. There was an unexpected decrease in aneuploid fetuses diagnosed over the study period, which could reflect decisions regarding genetically abnormal fetuses being made without a definitive diagnostic procedure.
This study was presented as a poster at the Annual Pregnancy Meeting of the Society for Maternal Fetal Medicine in Las Vegas, Nevada on January 26, 2017.
- 1 Lo YM, Corbetta N, Chamberlain PF. , et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350 (9076): 485-487
- 2 Ehrich M, Deciu C, Zwiefelhofer T. , et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204 (03) 205.e1-205.e11
- 3 Palomaki GE, Kloza EM, Lambert-Messerlian GM. , et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13 (11) 913-920
- 4 Palomaki GE, Deciu C, Kloza EM. , et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012; 14 (03) 296-305
- 5 Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. ; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119 (05) 890-901
- 6 Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206 (04) 319.e1-319.e9
- 7 Norton ME, Brar H, Weiss J. , et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207 (02) 137.e1-137.e8
- 8 Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Uptake of noninvasive prenatal testing at a large academic referral center. Am J Obstet Gynecol 2014; 211 (06) 651.e1-651.e7
- 9 Friel LA, Czerwinski JL, Singletary CN. The impact of noninvasive prenatal testing on the practice of maternal-fetal medicine. Am J Perinatol 2014; 31 (09) 759-764
- 10 Platt LD, Janicki MB, Prosen T. , et al. Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. Am J Obstet Gynecol 2014; 211 (04) 368.e1-368.e7
- 11 Wax JR, Cartin A, Chard R, Lucas FL, Pinette MG. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection. J Clin Ultrasound 2015; 43 (01) 1-6
- 12 Williams III J, Rad S, Beauchamp S. , et al. Utilization of noninvasive prenatal testing: impact on referrals for diagnostic testing. Am J Obstet Gynecol 2015; 213 (01) 102.e1-102.e6
- 13 Li DZ, Zhen L, Pan M, Han J, Yang X, Ou YM. Non-invasive prenatal testing: impact on invasive prenatal diagnosis at a mainland Chinese tertiary medical center. J Matern Fetal Neonatal Med 2016; 29 (21) 3539-3541
- 14 Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn 2015; 35 (10) 972-979
- 15 Press N, Browner CH. Why women say yes to prenatal diagnosis. Soc Sci Med 1997; 45 (07) 979-989
- 16 Tischler R, Hudgins L, Blumenfeld YJ, Greely HT, Ormond KE. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011; 31 (13) 1292-1299
- 17 Kaimal AJ, Norton ME, Kuppermann M. Prenatal testing in the genomic age. Clinical outcomes, quality of live and costs. Obstet Gynecol 2015; 126 (04) 737-746
- 18 Suskin BG, Sciscione AM, Teigen N. , et al. Revisiting the challenges of training maternal fetal medicine fellows in chorionic villus sampling. Am J Obstet Gynecol 2016; 215 (06) 777.e1-777.e4